Traditional drugs or therapies rarely have effects on regression of chronic liver diseases,
which result in many cases from sustained oxidative stress. In recent years, ellagic acid (EA) …

Isoniazid (INH) remains a mainstay for the treatment of tuberculosis despite the fact that it
can cause liver failure. Previous mechanistic hypotheses have classified this type of drug …

Current drug-safety assays for hepatotoxicity rely on biomarkers with low predictive power.
The production of radical species, specifically reactive oxygen species (ROS) and reactive …

Protoporphyrin IX (PPIX) is an intermediate in the heme biosynthesis pathway. Abnormal
accumulation of PPIX due to certain pathological conditions such as erythropoietic …

The gut microbiome harbors trillions of organisms that contribute to human health and
disease. These bacteria can also affect the properties of medical drugs used to treat these …

The emergent discipline of metabolomics has attracted considerable research effort in
hepatology. Here we review the metabolomic data for non-alcoholic fatty liver disease …

Drug‐induced liver injury (DILI) is a major challenge in clinical medicine and drug
development. New models are needed for predicting which potential therapeutic …

Isoniazid (INH) and rifampicin (RFP) are the first-line medications for tuberculosis treatment,
and liver injury is the major adverse effect. Natural medicinal ingredients provide distinct …

Idiosyncratic drug-induced liver injury (iDILI) encompasses the unexpected harms that
prescription and non-prescription drugs, herbal and dietary supplements can cause to the …

Abstract Purpose of Review This article provides a brief overview of mechanisms of
inflammatory liver injury and how this applies to drug hepatotoxicity with a particular …